MTOR and autoimmune thrombocytopenic purpura: mTOR inhibitors (e.g., rapamycin) can reduce the aberrant activation of moDCs in ITP patients, enhance the release of immunosuppressive cytokines, and partially restore Treg functionality [64, 65].